Author

Fritz Sorgel

Professor Pharmakologie - Cited by 11,328 - Antibiotika - Pharmakokinetik

Biography

Fritz Sorgel works as the Director, Institute of Biomedical and Pharmaceutical Research, Germany. he has written an editorial on Journal of Bioequivalence & Bioavailability. His current research is on Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections  
Title
Cited by
Year
Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta …
C Lübbert, C Baars, A Dayakar, N Lippmann, AC Rodloff, M Kinzig, ...Infection 45 (4), 479-491, 2017201
163
2017
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
M Schiestl, M Zabransky, F SörgelDrug design, development and therapy, 1509-1515, 2017201
82
2017
The contamination of valsartan and other sartans, part 1: New findings
F Sörgel, M Kinzig, M Abdel-Tawab, C Bidmon, A Schreiber, S Ermel, ...Journal of pharmaceutical and biomedical analysis 172, 395-405, 2019201
55
2019
A systematic review of the stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates
M Zilker, F Sörgel, U HolzgrabeJournal of pharmaceutical and biomedical analysis 166, 222-235, 2019201
44
2019
N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance
F Higel, T Sandl, CY Kao, N Pechinger, F Sörgel, W Friess, F Wolschin, ...European Journal of Pharmaceutics and Biopharmaceutics 139, 123-131, 2019201
42
2019
Assessment of pharmacokinetic drug–drug interactions in humans: in vivo probe substrates for drug metabolism and drug transport revisited
U Fuhr, C Hsin, X Li, W Jabrane, F SörgelAnnual review of pharmacology and toxicology 59, 507-5, 2019201
36
2019
The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities
O Scherf-Clavel, M Kinzig, A Besa, A Schreiber, C Bidmon, ...Journal of Pharmaceutical and Biomedical Analysis 172, 278-284, 2019201
35
2019
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis
F Sörgel, JJ Malin, H Hagmann, M Kinzig, M Bilal, DA Eichenauer, ...Journal of Antimicrobial Chemotherapy 76 (3), 825-827, 2021202
35
2021
Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients
PS Zeiner, M Kinzig, I Divé, GD Maurer, K Filipski, PN Harter, C Senft, ...Journal of Clinical Medicine 8 (12), 2031, 2019201
22
2019
Population modeling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics, and clinical outcome in patients with sunitinib‐treated cancer
MH Diekstra, A Fritsch, F Kanefendt, JJ Swen, D Moes, F Sörgel, M Kinzig, ...CPT: pharmacometrics & systems pharmacology 6 (9), 604-613, 2017201
21
2017
A clinical drug‐drug interaction study assessing a novel drug transporter phenotyping cocktail with adefovir, sitagliptin, metformin, pitavastatin, and digoxin
C Trueck, C Hsin, O Scherf‐Clavel, E Schaeffeler, R Lenssen, M Gazzaz, ...Clinical pharmacology & therapeutics 106 (6), 1398-1407, 2019201
21
2019
Drinking ethanol has few acute effects on CYP2C9, CYP2C19, NAT2, and P‐glycoprotein activities but somewhat inhibits CYP1A2, CYP2D6, and intestinal CYP3A: so what?
M Gazzaz, M Kinzig, E Schaeffeler, M Jübner, C Hsin, X Li, M Taubert, ...Clinical Pharmacology & Therapeutics 104 (6), 1249-1259, 2018201
17
2018
Four decades of β-lactam antibiotic pharmacokinetics in cystic fibrosis
JB Bulitta, Y Jiao, SK Drescher, A Oliver, A Louie, B Moya, X Tao, ...Clinical Pharmacokinetics 58, 143-6, 2019201
15
2019
The nitrosamine contamination of drugs, part 3: Quantification of 4-Methyl-1-nitrosopiperazine in rifampicin capsules by LC-MS/HRMS
J Wohlfart, O Scherf-Clavel, M Kinzig, F Sörgel, U HolzgrabeJournal of Pharmaceutical and Biomedical Analysis 203, 114205, 2021202
13
2021
Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: a phase I trial with early pharmacodynamic FDG‐PET assessment
L Nogova, C Mattonet, M Scheffler, M Taubert, M Gardizi, ML Sos, ...Cancer Medicine 9 (14), 4991-5007, 2020202
12
2020
Pharmacokinetics and pharmacodynamics of antibiotics in bone
CB Landersdorfer, JB Bulitta, RL Nation, F SörgelBone and joint infections: from microbiology to diagnostics and treatment, 81-98, 2021202
11
2021
Novel population pharmacokinetic approach to explain the differences between cystic fibrosis patients and healthy volunteers via protein binding
NR Shah, JB Bulitta, M Kinzig, CB Landersdorfer, Y Jiao, DS Sutaria, ...Pharmaceutics (6), 286, 2019201
11
2019
Azathioprine-induced reversible EBV-associated Hodgkin-like lymphoma after immunosuppressive therapy for autoimmune hepatitis
M Munz, D Pretscher, M Wilhelm, U Holzgrabe, F Sörgel, J BirkmannInternational Journal of Clinical Pharmacology and Therapeutics 56 (3), 142, 2018201
10
2018
Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis
R Höhl, R Bertram, M Kinzig, GS Haarmeyer, M Baumgärtel, A Geise, ...Mycoses 65 (7), 747-752, 2022202
10
2022
A stability-study of expired ampoules manufactured more than 40 years ago
M Zilker, F Sörgel, U HolzgrabeJournal of Pharmaceutical and Biomedical Analysis 150, 318-326, 2018201
9
2018

Referred From: https://scholar.google.de/citations?user=vGvosksAAAAJ&hl=de

Cited by
Citations 11328
h-index 56
i10-index 182
Recommended Journals
Open Access Journals